Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe...
ETR: BAYN
Bayer’s Kerendia Gets FDA Priority Review for Heart Failure with Preserved Ejection Fraction
German pharmaceutical giant Bayer (ETR: BAYN) announced that a supplementary New Drug Application (sNDA) for...
Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way
German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...
Bayer HealthCare and JD Healthcare Partner on Women’s Health Ecosystem
German pharmaceutical giant Bayer HealthCare (ETR: BAYN) has entered into a new partnership with JD...
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...
Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease
German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...
Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals
Bayer (ETR: BAYN) has submitted a marketing application to the European Medicines Agency (EMA) for...
Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech
Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication
Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...
EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment
Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...
Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I...
Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation
Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...
Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care
Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...
Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation
Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...
Bayer’s Nubeqa Files for FDA Approval in mHSPC
German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...